Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

ABUS

Arbutus Biopharma Corp

Dec 11 • 04:00PM ET

3.64

Dollar change -0.12
Percentage change -3.19	%

Healthcare • Biotechnology • USA • NASD

Peers: GILD REGN ALNY MRNA VRTX EXEL NBIX BMRN SRPT BLUE

| Held by: VTI IWM VXF IWO XBI IBB SCHA VTWO IWC ESML

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.43	Insider Own	22.31%	Shs Outstand	189.44M	Perf Week	-2.67%
Market Cap	689.75M	Forward P/E	-	EPS next Y	-0.34	Insider Trans	-0.02%	Shs Float	147.22M	Perf Month	-2.41%
Income	-76.70M	PEG	-	EPS next Q	-0.08	Inst Own	53.49%	Short Float	3.95%	Perf Quarter	-15.55%
Sales	6.74M	P/S	102.34	EPS this Y	11.82%	Inst Trans	5.45%	Short Ratio	5.73	Perf Half Y	12.00%
Book/sh	0.56	P/B	6.45	EPS next Y	11.86%	ROA	-51.29%	Short Interest	5.82M	Perf Year	77.56%
Cash/sh	0.67	P/C	5.40	EPS next 5Y	-	ROE	-67.81%	52W Range	1.98 - 4.72	Perf YTD	45.60%
Dividend Est.	-	P/FCF	-	EPS past 5Y	18.41%	ROI	-67.77%	52W High	-22.96%	Beta	1.77
Dividend TTM	-	Quick Ratio	7.02	Sales past 5Y	55.33%	Gross Margin	79.15%	52W Low	83.84%	ATR (14)	0.14
Dividend Ex-Date	-	Current Ratio	7.02	EPS Y/Y TTM	8.60%	Oper. Margin	-1165.03%	RSI (14)	49.41	Volatility	3.70% 4.06%
Employees	73	Debt/Eq	0.06	Sales Y/Y TTM	-69.69%	Profit Margin	-1137.64%	Recom	1.40	Target Price	5.20
Option/Short	Yes / Yes	LT Debt/Eq	0.06	EPS Q/Q	13.08%	Payout	-	Rel Volume	0.63	Prev Close	3.76
Sales Surprise	-28.00%	EPS Surprise	-6.38%	Sales Q/Q	-71.25%	Earnings	Nov 06 BMO	Avg Volume	1.02M	Price	3.64
SMA20	2.39%	SMA50	-3.54%	SMA200	6.25%	Trades		Volume	639,425	Change	-3.19%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-02-22	Upgrade	Jefferies	Hold → Buy	$5
Feb-25-21	Initiated	Jefferies	Hold	$5
Dec-17-20	Initiated	H.C. Wainwright	Buy	$10
Jul-27-20	Resumed	JMP Securities	Mkt Outperform	$10 → $8
Jul-24-20	Downgrade	Robert W. Baird	Outperform → Neutral
May-19-20	Upgrade	Wedbush	Neutral → Outperform
Mar-06-20	Upgrade	Chardan Capital Markets	Neutral → Buy	$5
Feb-20-20	Initiated	Robert W. Baird	Outperform	$8
Feb-05-20	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform	$10
Oct-07-19	Reiterated	B. Riley FBR	Buy	$7 → $3
Oct-04-19	Downgrade	Chardan Capital Markets	Buy → Neutral
Oct-16-18	Upgrade	B. Riley FBR	Neutral → Buy	$11.50 → $9
Oct-15-18	Upgrade	Wedbush	Underperform → Neutral	$5
Oct-12-18	Reiterated	Chardan Capital Markets	Buy	$12 → $6.50
Jul-06-18	Downgrade	B. Riley FBR, Inc.	Buy → Neutral	$9 → $9
Mar-19-18	Resumed	Chardan Capital Markets	Buy	$8.25
Mar-19-18	Downgrade	Wedbush	Outperform → Neutral	$9 → $6
Jan-05-18	Initiated	B. Riley FBR, Inc.	Buy	$10
Apr-04-17	Upgrade	Chardan Capital Markets	Neutral → Buy	$3 → $6
Feb-01-17	Reiterated	Wedbush	Outperform	$13 → $10

Show Previous Ratings

Dec-06-24 08:20AM	Heres Why Arbutus (ABUS) Surged in Q3 (Insider Monkey)
Dec-03-24 08:00AM	Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors (Business Wire)
Nov-26-24 07:30AM	Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat (GlobeNewswire)
Nov-15-24 11:02AM	Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon (GlobeNewswire)
11:01AM	Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B (GlobeNewswire)
07:30AM	Loading…
Nov-14-24 07:30AM	Arbutus to Present at Jefferies London Healthcare Conference (GlobeNewswire)
Nov-07-24 02:12AM	Arbutus Biopharma Corp (ABUS) Q3 2024 Earnings Call Highlights: Promising Clinical Trials and ... (GuruFocus.com)
02:07AM	Q3 2024 Arbutus Biopharma Corp Earnings Call (Thomson Reuters StreetEvents)
Nov-06-24 08:45AM	Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:40AM	Arbutus: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-23-24 07:30AM	Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update (GlobeNewswire)
Oct-15-24 08:16AM	Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting 2024 (GlobeNewswire) +6.48%
Oct-01-24 07:30AM	Arbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference (GlobeNewswire)
Sep-25-24 09:40AM	Has Arbutus Biopharma (ABUS) Outpaced Other Medical Stocks This Year? (Zacks)
07:30AM	Loading…
Sep-03-24 07:30AM	Arbutus to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Aug-22-24 09:40AM	Is Arbutus Biopharma (ABUS) Stock Outpacing Its Medical Peers This Year? (Zacks)
Aug-06-24 09:40AM	Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year? (Zacks)
Aug-02-24 01:51AM	Q2 2024 Arbutus Biopharma Corp Earnings Call (Thomson Reuters StreetEvents)
Aug-01-24 08:40AM	Arbutus Biopharma (ABUS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:41AM	Arbutus: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-18-24 07:30AM	Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update (GlobeNewswire)
Jun-06-24 11:15AM	Treatment with Arbutus' Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels (GlobeNewswire) -7.99%
11:15AM	Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B (GlobeNewswire)
Jun-05-24 02:30AM	Arbutus' Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure (GlobeNewswire) +8.68%
May-29-24 07:30AM	Arbutus to Participate in Jefferies Global Healthcare Conference (GlobeNewswire)
May-22-24 02:00AM	Arbutus to Present Imdusiran Data at EASL Congress 2024 (GlobeNewswire) +6.23%
May-17-24 12:03PM	Update: Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program (MT Newswires)
10:40AM	Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program (MT Newswires)
09:00AM	Loading…
09:00AM	Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value (Business Wire)
May-07-24 07:30AM	Arbutus to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
May-03-24 11:19AM	Arbutus Biopharma Corporation (NASDAQ:ABUS) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:24AM	Arbutus Biopharma Corp (ABUS) Q1 2024 Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
May-02-24 12:55PM	ABUS Stock Earnings: Arbutus Biopharma Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:58AM	Arbutus Biopharma Corp Reports Q1 2024 Earnings: A Detailed Financial Review (GuruFocus.com)
08:45AM	Arbutus Biopharma (ABUS) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:44AM	Arbutus: Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
07:25AM	Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024 (GlobeNewswire)
Apr-30-24 09:40AM	Are Medical Stocks Lagging Arbutus Biopharma (ABUS) This Year? (Zacks)
Apr-18-24 07:30AM	Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update (GlobeNewswire)
Apr-04-24 08:30AM	Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna (GlobeNewswire)
Mar-08-24 07:30AM	Arbutus to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Mar-01-24 08:17AM	Arbutus Biopharma Corporation (NASDAQ:ABUS) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-29-24 11:14PM	Q4 2023 Arbutus Biopharma Corp Earnings Call (Thomson Reuters StreetEvents)
08:40AM	Arbutus Biopharma (ABUS) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:52AM	Arbutus Biopharma Corp (ABUS) Reports Year-End Financial Results and Progress in Clinical Trials (GuruFocus.com)
07:30AM	Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-15-24 07:30AM	Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update (GlobeNewswire)
Jan-08-24 07:30AM	Arbutus Announces 2024 Corporate Objectives and Provides Financial Update (GlobeNewswire)
Nov-09-23 04:24PM	Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD (GlobeNewswire)
04:01PM	Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting (GlobeNewswire)
09:12AM	Arbutus Biopharma Corporation (NASDAQ:ABUS) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 07:30AM	Arbutus to Present at Jefferies London Healthcare Conference (GlobeNewswire)
01:16AM	Q3 2023 Arbutus Biopharma Corp Earnings Call (Thomson Reuters StreetEvents)
Nov-07-23 08:05AM	Arbutus Biopharma Corp (ABUS) Reports Q3 2023 Financial Results (GuruFocus.com)
07:40AM	Arbutus: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
07:15AM	Arbutus Announces CEO, William Collier, to Retire December 31, 2023 (GlobeNewswire)
Oct-30-23 09:32AM	12 Best Micro Cap Stocks To Invest In (Insider Monkey)
Oct-24-23 07:30AM	Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update (GlobeNewswire)
Oct-18-23 07:30AM	Arbutus to Present at H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference (GlobeNewswire) -5.82%
Oct-11-23 08:05AM	Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting 2023 (GlobeNewswire)
Sep-12-23 10:56AM	Arbutus BioPharma narrows research focus to extend cash runway (American City Business Journals) -7.73%
08:58AM	Arbutus (ABUS) to Focus on Hepatitis B Candidates, Stock Up (Zacks)
Sep-11-23 04:15PM	Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway Extended (GlobeNewswire)
Sep-07-23 07:30AM	Arbutus to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Aug-04-23 03:29PM	Arbutus Biopharma Corporation (NASDAQ:ABUS) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-03-23 08:55AM	Arbutus Biopharma (ABUS) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:49AM	Arbutus: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update (GlobeNewswire)
Jul-23-23 10:19AM	Arbutus Biopharma Corporation (NASDAQ:ABUS) has caught the attention of institutional investors who hold a sizeable 38% stake (Simply Wall St.)
Jul-20-23 07:30AM	Arbutus to Report Second Quarter 2023 Financial Results and Provide Corporate Update (GlobeNewswire)
Jul-12-23 07:30AM	Arbutus Appoints Melissa V. Rewolinski, PhD to its Board of Directors (GlobeNewswire)
Jul-10-23 04:01PM	Arbutus Appoints Two New Executives (GlobeNewswire)
Jun-23-23 09:40AM	Are Medical Stocks Lagging Amphastar Pharmaceuticals (AMPH) This Year? (Zacks)
Jun-21-23 07:30AM	Arbutus Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial that Includes a PD-1 Monoclonal Antibody (GlobeNewswire)
02:01AM	Arbutus Presents Preliminary AB-729 and Pegylated Interferon Alfa-2a Combination Data at the EASL Congress 2023 (GlobeNewswire)
Jun-07-23 09:40AM	Is Amphastar Pharmaceuticals (AMPH) Stock Outpacing Its Medical Peers This Year? (Zacks)
02:01AM	Arbutus to Present AB-729 and AB-836 Data at EASL Congress 2023 (GlobeNewswire)
Jun-01-23 11:29AM	Biohaven (BHVN) Stock up 8% on Encouraging Pipeline Updates (Zacks)
May-31-23 07:30AM	Arbutus to Present at Jefferies Healthcare Conference (GlobeNewswire)
May-30-23 09:26AM	Valneva (VALN) Stock Down 53% in the Past Year: Here's Why (Zacks)
May-29-23 10:08AM	FDA Accepts Iovance's (IOVA) BLA Filing for Melanoma Drug (Zacks)
May-22-23 09:40AM	Is Amphastar Pharmaceuticals (AMPH) Outperforming Other Medical Stocks This Year? (Zacks)
May-17-23 07:38AM	Here's Why We're Watching Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Situation (Simply Wall St.)
May-09-23 12:00PM	Arbutus (ABUS) Upgraded to Buy: Here's Why (Zacks)
07:30AM	Arbutus to Present at JMP Securities Life Sciences Conference (GlobeNewswire)
May-04-23 11:52PM	Q1 2023 Arbutus Biopharma Corp Earnings Call (Thomson Reuters StreetEvents)
09:40AM	Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year? (Zacks)
08:55AM	Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Arbutus Reports First Quarter 2023 Financial Results and Corporate Update (GlobeNewswire)
Apr-27-23 03:20AM	Arbutus Provides AB-729 Clinical Data and AB-161 Preclinical Data as Oral Presentations at the Global Hepatitis Summit 2023 (GlobeNewswire)
Apr-25-23 11:57AM	Why Arbutus Biopharma Stock Is Plunging Today (Benzinga) -12.46%
11:50AM	Why Arbutus Biopharma Stock Is Sinking Today (Motley Fool)
07:30AM	Arbutus Announces FDA Clinical Hold on IND Application for AB-101, an oral PD-L1 inhibitor (GlobeNewswire)
Apr-20-23 07:30AM	Arbutus to Report First Quarter 2023 Financial Results and Provide Corporate Update (GlobeNewswire)
Apr-18-23 04:01PM	Arbutus to Present AB-729 and AB-161 Data at the Global Hepatitis Summit 2023 (GlobeNewswire)
02:18PM	Arbutus Biopharma Corporation's (NASDAQ:ABUS) Share Price Could Signal Some Risk (Simply Wall St.)

Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the Hepatitis B virus, SARS-CoV-2, and other coronaviruses. The company was founded on October 6, 2005 and is headquartered in Warminster, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MANCHESTER KEITH S	Director	Aug 14 '24	Option Exercise	0.56	54,915	30,752	54,915	Aug 16 04:07 PM
MANCHESTER KEITH S	Director	Aug 14 '24	Sale	3.69	8,846	32,637	46,069	Aug 16 04:07 PM
Sims Karen	Chief Medical Officer	Feb 02 '24	Sale	2.31	4,358	10,078	125,542	Feb 05 07:55 PM
HASTINGS DAVID C	Chief Financial Officer	Feb 02 '24	Sale	2.31	9,593	22,184	181,907	Feb 05 07:54 PM
Sofia Michael J.	Chief Scientific Officer	Feb 02 '24	Sale	2.31	9,982	23,083	1,485,121	Feb 05 07:54 PM
McElhaugh Michael J.	Interim President & CEO	Feb 02 '24	Sale	2.31	10,164	23,504	1,504,793	Feb 05 07:54 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ABUS

Arbutus Biopharma Corp

Upgrade your FINVIZ experience